











2442Hollow Mesoporous Zirconia Nanocapsules for
Drug DeliveryBy Shaoheng Tang, Xiaoqing Huang, Xiaolan Chen, and Nanfeng Zheng*Hollow mesoporous zirconia nanocapsules (hm-ZrO2) with a hollow core/
porous shell structure are demonstrated as effective vehicles for anti-cancer
drug delivery. While the highly porous feature of the shell allows the drug,
doxorubicin(DOX), to easily pass through between the inner void space and
surrounding environment of the particles, the void space in the core endows
the nanocapsules with high drug loading capacity. The larger the inner hollow
diameter, the higher their DOX loading capacity. A loading of 102% related to
the weight of hm-ZrO2 is achieved by the nanocapsules with an inner
diameter of 385 nm. Due to their pH-dependent charge nature, hm-ZrO2
loaded DOX exhibit pH-dependent drug releasing kinetics. A lower pH offers
a faster DOX release rate from hm-ZrO2. Such a property makes the loaded
DOX easily release from the nanocapsules when up-taken by living cells.
Although the flow cytometry reveals more uptake of hm-ZrO2 particles by
normal cells, hm-ZrO2 loaded DOX release more drugs in cancer cells than in
normal cells, leading to more cytotoxicity toward tumor cells and less
cytotoxicity to healthy cells than free DOX.1. Introduction
Many cancer therapeutic agents kill both cancer and healthy cells,
causing numerous side effects.[1] To reduce the side effects, an
ideal drug delivery carrier should sequester the drugs before
reaching the targeted organs or cells. Owing to the enhanced
permeability and retention (EPR) effect,[2–3] nanosized drugs or
drug carriers can be heavily accumulated around tumor sites.[4–6]
When further conjugated with targeting agents (e.g., folic acid,
antibody, aptamer), the nanoscale drug carriers would achieve the
sustained drug release in cancer cells. However, to be successful,
the nanosized carriers should be stable enough to survive for
an extended period of time and carry enough anticancer drugs.
Due to their desirable biocompatibility, high drug loading
capacity, easy surface conjugation of biomolecules and excellent
stability, the application of inorganic nanomaterials in drug
delivery has therefore attracted increasing research attention in
past several years.[7] These nanomaterials include inorganic[*] Prof. N. F. Zheng, S. H. Tang, X. Q. Huang, Prof. L. X. Chen
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 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimnanoparticles,[8–12] mesoporous materi-
als,[13–27] nanotubes,[28–33] hollow nanos-
tructures,[34–36] and so on.[37–39]
Drugs are typically loaded in inorganic
high-surface carriers through weak non-
covalent interactions, such as physical
adsorption, electrostatic interaction, hydro-
gen bonding, and p–p stacking. Therefore,
the release of loadeddrugs from the carriers
can be easily triggered by breaking theweak
interactions between the drug guests and
inorganic host. To ensure the zero drug
releasebefore the triggering signal, inmany
studies, the exit pathways of the drugs are
functionalized by pore-blocking agents,
which can be degraded or structurally
switched by the drug release signal.[40,41]
By utilizing the surface binding difference
between cancer cells and normal cells,
tumor cells specific delivery were mainly
achieved by incorporating targeting agents
on the surface of the drug carriers. Besidesthe difference in surface recognition, cancer cells have a more
acidic environment and increasedmetabolic rate relative tohealthy
cells.[42,43] One would wonder whether it is possible to take
advantage of this difference to distinguish drug release in tumor
and healthy cells without the help from targeting agents.
Unexpectedly, we have now found that when loaded with
anticancer drugs, inorganic hollow mesoporous nanocapsules
behave differently in cancer and normal cells. The hollow
mesoporous zirconia nanocapsules (hm-ZrO2) are highly bio-
compatible and exhibit high loading capacity of doxorubicin
(DOX).TheDOXloaded in themesoporousnanocapsules exhibit a
pH-dependent release behavior. The lower pH, the faster is the
DOX releasing rate. When up-taken by cells, the loaded DOX gets
released from the nanocapsules by the lowered pH caused by the
subcellular lysosomal compartments. The flow cytometry demon-
strated thatmorehm-ZrO2wereuptakenbynormal cells.However,
due to the more acidic environment in tumor cells, hm-ZrO2
loaded DOX release more drugs in cancer cells but not in normal
cells in the sameperiod, displayingmore cytotoxicity toward tumor
cells and less cytotoxicity to healthy cells than free DOX.2. Results and Discussion
Hollowmesoporous-ZrO2 (hm-ZrO2) nanocapsules with different











www.afm-journal.demade using a modified literature method.[44–46] Briefly, mono-
dispersed silica nanospheres with different sizes were first made
according to the well-known Stöber’s method. The uniform SiO2
spheres were then coated with a layer of zirconia through
hydrolysis of Zr(OBu)4 in the presence of Brij 30. After being aged
in water for 12 h, the particles were dried and then calcined at
850 8C before they were treated with NaOH solution (5 M). Such a
treatment removed silica to create hm-ZrO2 nanocapsules. The
thickness of porous ZrO2 layer is approximately 15 nm. Shown in
Figure 1a–d are images of SiO2 templates (385-nm), SiO2@ZrO2,
and also the resulting hm-ZrO2 with an inner diameter of 385 nm.
As revealed in the TEM image, the important structural feature of
the as-prepared ZrO2 nanospheres is that they are hollow
mesoporous. Such a feature is highly desirable for drug delivery
applications.While the void space inside the particles is important
to increase their drug loading capacity, the porosity in the shell is
necessary for drugs to pass through between inner void space and
surrounding environment of the particles. The fabrication of the
nanocapsules reported here used the Stöber silica spheres as the
templates, allowing us to easily prepare hm-ZrO2 with various
inner diameters. In this work, hm-ZrO2 with inner diameters of
110-, 150-, and 385-nm were prepared.
N2 adsorption measurements were further used to confirm the
mesoporosity of the as-preparedhm-ZrO2 (Fig. 2). TheBETsurface
area and pore volume of the nanocapsules fabricated by using
385-nm silica templates are 222m2 g1 and 0.213 cm3 g1,
respectively. Based on the analysis of the adsorption branch of
the isothermbyusing theDFTmethod, thepore sizedistribution is
centered around 3.6 nm. In comparison, before the removal of
SiO2 core, theBETsurface area andpore volumeof the particles are
113m2 g1 and 0.08 cm3 g1, respectively. Although the surface
area and pore volume of hm-ZrO2 are both larger than those of
unetched SiO2@ZrO2 particles, it should be noted that theFigure 1. Representative SEM images of a) 385-nm SiO2 templates,
b) SiO2@ZrO2 intermediate particles and c) hm-ZrO2. d) TEM image of
hm-ZrO2 synthesized from 385-nm SiO2.
Figure 2. a,b) N2 adsorption-desorption isotherms and pore-size distri-
bution (inset) of a) hm-ZrO2 and b) SiO2@ZrO2 intermediate particles
synthesized from 385-nm SiO2. c) The pH dependent zeta-potential of hm-
ZrO2 synthesized from 385-nm SiO2.
Adv. Funct. Mater. 2010, 20, 2442–2447  2010 WILEY-VCH Verlsignificant mesoporosity is also present in SiO2@ZrO2. The
energy dispersive X-ray spectrum (EDX) of the prepared
nanocapsules shows that a small amount of silica remains in
the porous shell. This compositional feature leaves a significant
impact on the isoelectric point of the nanocapsules. Pure ZrO2 has
an isoelectric point around pH 6.5. As revealed by pH-dependent
zeta-potential measurements, having a small amount of silica in
hm-ZrO2hashowever resulted in adecrease in the isoelectric point
from 6.5 to 3.4 (Fig. 2c). Consequently, while there is no dramatic












2444decrease of the negative zeta potential value is noticeable
when pH is below 7. Such a zeta potential profile is very important
since the particles taken up by cells from the blood stream would
also undergo a pH change from 7.4 to a lower pH, which is
caused by subcellular lysosomal compartments (i.e., endosomes,
lysosomes).
Considering that hm-ZrO2 nanoparticles are rather negatively
chargedatpHabove7,wehave selecteddrugdoxorubicin (DOX)as
a model drug, a commonly used chemotherapeutic agent, to
investigate hm-ZrO2 as a candidate of drug delivery vehicles.
Water-soluble DOX in the form of hydrochloride salt was used in
our drug loading studies. When a solution of DOX is added into a
water dispersion of hm-ZrO2, a quick loading was observed. The
facile loading of the protonated DOX molecules on hm-ZrO2
nanocapsules is likely due to the high negative charge of hm-ZrO2
at pH7 and therefore strong electrostatic interactionswithDOX.
Upon centrifuging, a red-colored solid of DOX-loaded hm-ZrO2
(hm-ZrO2-DOX) is readily separated from a decolored liquid. As
depicted in Figure 3a, FT-IR spectra of DOX-loaded hm-ZrO2
display all characteristic IR peaks of freeDOX,which confirms the
immobilization of DOX on hm-ZrO2 without changing their
structure. In contrast to IR, the photoluminescence of loaded
DOX molecules is significantly quenched (Fig. 3b), which is alsoFigure 3. a) FT-IR spectra of free DOX, hm-ZrO2 and hm-ZrO2 loaded
DOX. b) Fluorescence spectra of free DOX and DOX-loaded hm-ZrO2.
 2010 WILEY-VCH Verlag GmbH & Cpreviously observed when they are loaded on carbon nanotubes
or graphene oxide.[47,48] When excited at 479 nm, free DOX in an
aqueous solution displays strong emission with the maximum at
555 nm. However, DOX loaded in hm-ZrO2 exhibits very weak
emission. The photoluminescence quenching indicates the
interactions among DOX molecules loaded in the nanocapsules.
Such a quenching turns out to be beneficial to the direct
observation of drug release in living cells that will discuss later
in this article.
To evaluate the effect of the void space on the drug loading in
the zirconia nanocapsules, the drug loading capacities of hm-ZrO2
with inner diameters of 110-, 150-, and 385-nmwere compared. As
illustrated in Figure 4a, the hollow nature endows the nanocap-
sules with high drug loading capacity. Here we specify the loading
capacity as the percentage of the weight of loaded DOX related
to the weight of hm-ZrO2. Maximum DOX loadings were
measured to be 52, 68, and 102wt% for hm-ZrO2 with inner
diameters of 110-, 150-, and 385-nm, respectively. The larger the
hollow inner diameter, the higher is the loading of DOX. Together
with their high loading, such a size-dependent DOX loading
indicates the occupation of inner hollow space ofhm-ZrO2 byDOX
molecules. This deduction is further supported by our loading
experiments on SiO2@ZrO2 particles also having high porous
ZrO2 shell but unetched inner SiO2 template. Even though these
SiO2@ZrO2 particles have a high surface area of 113m
2 g1 and
pore volume of 0.08 cm3 g1, the DOX loading is however almostFigure 4. a) DOX loading capacity of SiO2@ZrO2 and hm-ZrO2 with
various hollow diameters. b) pH-dependent releasing kinetics of DOX
from hm-ZrO2-DOX.












Figure 6. Fluorescencemicroscopic images of QGY-7703 cells (a) and QSG-
7701 cells (b) after being incubated with hm-ZrO2-DOX for 12 h. Relative cell
viability data ofQSG-7703 cells (c) andQGY-7701 cells (d) incubated with free
DOX and hm-ZrO2-DOX at different concentrations.negligible (<0.1wt%) for these spheres. This result confirms that
themesoporous shell is not themain contributor to the high DOX
loading capacity of the hm-ZrO2 nanocapsules.
Having the high drug loading and the porous shell materials
with charge tunable by pH, hm-ZrO2 nanocapsules are expected as
an excellent candidate for intracellular drug vehicles. To measure
the release kinetics of DOX-loaded hm-ZrO2, we dispersed DOX-
loaded nanocapsules in buffer solutions with various pH (i.e., 7.4,
6.6, 5.2, 3.6). Figure 4b shows the pH-dependent DOX release
kinetics. Regardless the pH value, DOX-loaded hm-ZrO2 exhibit
sustained release properties with a relatively fast release at the
initial stage.However, theDOX release rate in the neutral solution
(pH7.4) is lower than that in the acidic solution (pH3.6). 7%, 15%,
25%, and 41% of the adsorbed DOX were released from loaded
capsuleswithin 48 h inPBSbuffer solutionsof pH7.4, 6.6, 5.2, and
3.6, respectively.
When taken up by living cells through endocytosis, particles
experience a pH drop to 5.5 or even lower. Therefore, the result
that the DOX releasing is faster in lower pH buffer has motivated
us to study the drug releasing process in living cells.
Biocompatibility of hm-ZrO2 was then examined before in vitro
drug delivery studies. The relative cell viabilities of human
hepatoma cells incubated with different concentrations of hm-
ZrO2 nanocapsules for 48 h were measured by MTT assay. As
shown in Figure 5 the concentration with 50% growth inhibition
(IC50) of hm-ZrO2 was determined up to 700mgmL
1, indicating
that hm-ZrO2 are highly biocompatible.
In contrast toDOX loaded on hm-ZrO2, freeDOXmolecules are
highly fluorescent. Owing to this property, it became possible to
usefluorescence signals tomonitor the drug releasing. The release
of DOX loaded on hm-ZrO2 was studied in both human hepatoma
cells (QGY-7703) and hepatocytes (QSG-7701) cells. To observe the
intracellular release of the drug in living cells by fluorescent
microscopy, the two cells were seeded on glass cover slips and
allowed to attach for 24 h. The cells were then further incubated in
the medium containing DOX-loaded hm-ZrO2 for 12 h. As
revealed by fluorescence micrographs (Fig. 6a,b), intense
fluorescence signals were observed inside the cells. Since theFigure 5. The relative cell viabilities of human hepatoma cells incubated
with different concentrations of hm-ZrO2 nanocapsules for 48 h.
Adv. Funct. Mater. 2010, 20, 2442–2447  2010 WILEY-VCH Verlfluorescence of DOX was significantly quenched when loaded
on hm-ZrO2, the appearance of fluorescence signals inside cells
indicated the actual release of DOX from hm-ZrO2.
Although the fluorescence microscopy provided straightfor-
ward imaging of the DOX release in cells, it would not
quantitatively determine and compare the released DOX amount
in QGY-7703 and QSG-7701 cells. Flow cytometry experiments
were then carried out to characterize the difference of DOX
releasing from hm-ZrO2 in cancer and normal cells. As clearly
illustrated inFigure 7a, theunexpected resultwas thatDOX-loaded
hm-ZrO2 released more DOX in hepatoma cells than hepatocytes
in the same period. Based on this result, a higher cytotoxicity of
DOX-loaded hm-ZrO2 should be expected in hepatoma cells. To
examine such an expectation, both cells were incubated with
mediumcontaindifferent concentrations ofDOX loadedhm-ZrO2
for 12 h. The relative cell viability was then measured by standard
MTT assay. As shown in Figure 6c and d, when the dosing DOX
concentration was higher than 20mM, DOX loaded hm-ZrO2 did
exhibit a higher cytotoxicity for hepatomas cells than hepatocytes.
With increased DOX dosing, the enhanced cytotoxicity became
greater for hepatoma cells. However, the situation in normal
hepatocytes is dramatically different. At all dosing concentrations,
free DOXmolecules weremore cytotoxic thanDOX loaded on hm-
ZrO2.
When loaded on hm-ZrO2, DOX killed more cancer cells but
not normal cells. To find the reason behind this observation, we
studied the uptake of Ru(BPy)3
2þ labeled hm-ZrO2 (hm-ZrO2-
Ru(BPy)3
2þ) particles by both hepatocytes and hepatoma cells.
Since the fluorescence of Ru(BPy)3
2þ is neither pHdependent nor
quenched upon loading on hm-ZrO2, the fluorescence intensity
detected in the living cells by the flow cytometry should be directly
correlated with the number of hm-ZrO2 nanocapsules taken by
the cells. As shown in Figure 7, the flow cytometric results












Figure 7. Flow cytometric profile of QSG-7701 cells and QGY-7703 cells
after being incubated with hm-ZrO2- DOX (a) and hm-ZrO2- Ru(bpy)3
2þ
(b) for 12 h.
2446hm-ZrO2 particles than hepatoma cells. Therefore, more DOX
release in hepatomas cells should not be attributed to more drug-
carrier uptake by the cancer cells. The faster release of drug from
hm-ZrO2 inside human hepatomas might be explained by the
lower pH in cancer cells than normal cells.[42,43]3. Conclusions
In summary,hollowmesoporouszirconiananocapsuleshavebeen
demonstrated as effective carriers offering high-loading of cancer
drugs. While the inorganic nanocapsules alone are highly
biocompatible, hm-ZrO2 loaded with DOX exhibit faster DOX
release and therefore a higher cytotoxicity for cancer cells than for
normal cells. In contrast to free DOX, hm-ZrO2 loaded DOX are
more toxic to cancer cells but less toxic to normal cells, which
makes them promising candidates for cancer drug carriers.4. Experimental
Reagents: Zr(OBu)4 (76%–80% in butanol) was purchased from Strem
Chemicals Inc. Tetraethoxysilane (TEOS) and Brij 30 were purchased from
Alfa Aesar. Ethanol, concentrated ammonia solution (28%–30% NH3 in
water) and NaOH were purchased from Sinopharm Chemical Reagent Co.
Ltd. (Shanghai, China). Human hepatoma cells (QGY-7703) and human 2010 WILEY-VCH Verlag GmbH & Chepatocytes (QSG-7701) were purchased from cell storeroom of Chinese
Academy of Science. RPMI 1640 cell culture medium, bovine serum
albumin (BSA) and Penicillin-Streptomycin compound were purchased
from Hyclone Laboratories Inc. MTT was purchased from Sigma.
Doxorubicin Hydrochloride was purchased from Beijing HuaFeng
United Technology CO., Ltd. The water used in all experiments was
ultrapure. All reagents were used as received without further purification.
Preparation of hm-ZrO2: Monodispersed silica particles with different
sizes were first made by the Stöber’s method. For the typical synthesis of
385 nm SiO2, 6.3mL concentrated ammonia, and 20mL water were added
to 150mL ethanol. After stirring for 30min, 12mL tetraethoxysilane was
added. The reaction mixture was further stirred for 8 h. The resultant
colloids were centrifuged, fully washed and redispersed in absolute 400mL
ethanol, 1.0mL water, and 1.0mL Brij30 and stirred for 30min before
6.0mL Zr(OBu)4 were added. The reaction mixture was stirred for another
8 h before the products were collected through centrifugation and
redispersed in water (40mL). After aging for 12 h, the composites were
collected, dried and calcined at 850 8C for 2 h. After cooling to room
temperature, the as-prepared SiO2@ZrO2 composites were treated with
NaOH (5M) for 20 h to remove silica. After silica removal, the obtained hm-
ZrO2 was washed and dried at 100 8C for further use.
Characterizations: TEM (including high-resolution transmission elec-
tron microscopy, HRTEM) studies were performed on a TECNAI F-30 high-
resolution transmission electron microscopy operating at 300 kV. SEM
studies were performed on a LEO1530 scanning electron microscopy with
a field emission electron gun. Flow cytometry (Becton Dickinson).
Fluorescence microscope (Nikon eclipse Ti-U).
Loading and Release of DOX: To measure the loading capacities of hm-
ZrO2, 0.4mL aqueous dispersion of nanocapsules(5mgmL
1) was added
into 3mL of 1.0mgmL1 DOX solution. After the mixture was shaken for
48 h, nanocapsules with adsorbed DOX were captured by centrifugation.
The solution was removed and assessed by UV-vis to identify the
concentrations of remained DOX. The loading capacity of the nanocap-
sules was calculated as the percentage of the weight of loaded DOX related
to the weight of hm-ZrO2. To study the drug release kinetics, the
nanocapsules loaded with DOXwere suspended into 5mL PBS buffers (pH
3.6, 5.2, 6.6, 7.4), and shaken at 100 rpm. At a given time, the sample was
captured by centrifugation, and 4mL aliquot of solution was removed for
the measurement of released DOX into the solution. 4mL of fresh buffer
solution was added to maintain the total volume of sample to 5mL. The
content of DOX in each withdrawn aliquot was measured by the
absorbance at 480 nm.
Cell Culture: Human hepatoma cells and human hepatocytes were
cultured on 100mm cell culture plate in RPMI 1640medium supplemented
with 10% calf serum, 100UmL1 penicillin, 100mgmL1 streptomycin in
37 8C, 5% CO2.
Apoptosis Assay: 0.2mL of 5mg mL1 hm-ZrO2 in water was mixed with
1.2mL DOX at 1.29 104 M, 7.10 105 M, 1,29 105 M, 7.10 106 M,
and 1.29 106 M. The mixtures were then shaken for overnight. Excess
DOX was removed by centrifuging. The cleaned hm-ZrO2-DOX were then
dispersed in 3.6mL of culture medium. For the in vitro cell toxicity assay,
cells were plated in 96-well plate in a density of about 1 104 cells per well
for 24 h. The medium was replaced by 0.2mL of cell medium containing
desired concentrations of hm-ZrO2-DOX or free DOX. After incubation for
12 h, cell viabilities were measured by standard MTT assay.
Intracellular Release Studies by Fluorescent Microscopy and Flow
Cytometry: DOX were loaded onto hm-ZrO2 by mixing 2mL of
7.0 105 M DOX with 1.5mg hm-ZrO2 in water overnight. To remove
unboundDOX, themixture was centrifuged, resuspended and washed with
PBS via ultrasonication for two times. The obtained DOX-loaded hm-ZrO2
was then dispersed in culture medium for fluorescence microscopy and
flow cytometry studies. For fluorescent microscopy analysis, human
hepatoma cells and human hepatocytes were plated in 24 well-plate with a
density of 0.5 104 cells per well. After incubation in fresh medium for
24 h, cells were incubated with 0.5mL of the medium containing
0.25mgmL1 hm-ZrO2-DOX for 12 h. The cell medium was removed,
and the cells were washed before PBS buffer solution was added. The











www.afm-journal.decytometry studies, the cells were incubated under similar conditions but in
a density of 0.5 105 cells per well. The adherent cells were detached
from the plate by treatment with trypsin-EDTA. The cells were then washed
and resuspended in PBS buffer solution for flow cytometry.
Uptake of [Ru(BPy)3]
2R Labeled hm-ZrO2 Studied by Flow Cytometry: To
prepare [Ru(BPy)3]
2þ labeled hm-ZrO2, 0.1mL of 4mM [Ru(BPy)3]Cl2
aqueous solution was injected into 0.4mL of 5mgmL1 hm-ZrO2
dispersion. After the mixture was stirred for 3 h at room temperature,
the particles were centrifuged, washed three times with deionized water
and then dispersed in 4mL culture medium. For flow cytometry analysis,
human hepatoma cells and hepatocytes were plated in 24 well-plate with a
density of0.5 105 cells per well. After incubation in the fresh RPMI 1640
medium for 24 h, cells were incubated with 0.5mL of the medium
containing 0.5mgmL1 [Ru(BPy)3]
2þ labeled hm-ZrO2 for 12 h. The cell
medium was removed, and the cells were washed with PBS buffer solution.
The adherent cells were detached from the plate by treatment with trypsin-
EDTA, washed and then suspended in PBS buffer solution for flow
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